

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## Peijia Medical Limited

### 沛嘉醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9996)

## VOLUNTARY ANNOUNCEMENT

### UNAUDITED OPERATING STATISTICS

#### FOR THE PERIOD FROM JANUARY 1, 2022 TO DECEMBER 31, 2022

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce certain unaudited operating statistics of the Group for the year ended December 31, 2022, and the comparative figures as set out below.

#### For the period from January 1 to December 31

	2022	2021	change
	<i>RMB' million</i>	<i>RMB' million</i>	<i>%</i>
Revenue	Approximately <b>240.0 - 260.0</b>	136.5	Approximately <b>75.8 - 90.4</b>

The increase in revenue was primarily attributable to the following reasons:

- (i) the commercialization of the Group’s transcatheter aortic valve replacement products (including the first-generation product TaurusOne® and second-generation retrievable product TaurusElite®) has accelerated; and

- (ii) the sales volume of the Group's existing neurointerventional products (including Tethys<sup>®</sup> Intermediate Catheter, SacSpeed<sup>®</sup> Balloon Dilatation Catheter and Jasper<sup>®</sup> SS Detachable Coil, etc.) has increased constantly, hence continuously contributing to the revenue growth of the Group.

The Company is in the process of finalizing the annual results of the Group for the year ended December 31, 2022. The above operating statistics is provided for investors' reference only and it shall not be taken as a measure or indication of the Group's future financial performance.

**SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE CAUTION WHEN DEALING IN THE SHARES OF THE COMPANY.**

By order of the Board  
**Peijia Medical Limited**  
**Dr. Yi Zhang**  
*Chairman and Executive Director*

Hong Kong, January 18, 2023

*As of the date of this announcement, the Board comprises Dr. Yi Zhang, Mrs. Ping Ye Zhang and Ms. Hong Ye as executive Directors, Dr. Zhiyun Yu, Mr. Jifeng Guan, Mr. Fei Chen, Mr. Jun Yang as non-executive Directors, and Dr. Stephen Newman Oesterle, Mr. Robert Ralph Parks, Mr. Wai Ming Yip, and Mr. Huacheng Wei as independent non-executive Directors.*